Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
774 studies found for:    Open Studies | "Lymphoma, Non-Hodgkin"
Show Display Options
Rank Status Study
21 Recruiting Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)
Conditions: Lymphoma, Non-Hodgkin;   Malaria;   Herpesvirus 4, Human
Intervention:
22 Unknown  Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Intervention: Procedure: Cytogenetic Analysis of Bone Marrow Specimen
23 Recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Cyclophosphamide;   Drug: Carmustine;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Antithymocyte globulin;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: rituximab
24 Recruiting Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Other: Database
25 Recruiting Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
26 Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Conditions: Lymphoma, Non-Hodgkin;   Cutaneous Lymphoma;   Cutaneous T Cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Brentuximab vedotin
27 Recruiting Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Intervention: Drug: Abraxane
28 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
29 Recruiting Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Conditions: Breast Neoplasms;   Ovarian Neoplasms;   Colonic Neoplasms;   Prostatic Neoplasms;   Uterine Cervical Neoplasms;   Leukemia;   Lymphoma, Non-Hodgkin
Intervention:
30 Unknown  A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
Conditions: Diffuse Large B Cell Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: Doxil;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim
31 Not yet recruiting Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Leukemia Acute Myeloid;   Lymphoma, Non-Hodgkin;   Myelodysplastic Syndrome;   Immunologic Deficiency Syndromes
Intervention: Biological: BPX-501 T cells and AP1903
32 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
33 Unknown  Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Conditions: Lymphoma, Non-Hodgkin;   Diffuse Large B-cell Lymphoma
Intervention: Drug: Rituximab, Cytarabine
34 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
35 Recruiting Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin
Interventions: Drug: Carmustine;   Drug: Etoposide phosphate;   Drug: Cytarabine;   Drug: Melphalan HCl (propylene glycol-free)
36 Recruiting Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin's Disease
Intervention:
37 Recruiting Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Biological: Ofatumumab;   Drug: Bendamustine
38 Recruiting BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826
39 Recruiting Study of Lymphoma in Asia
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myleoma;   Lympocytic, Follicular;   Leukemia;   Hodgkin Lymphoma
Intervention:
40 Recruiting Family Study of Lymphoproliferative Disorders
Conditions: Lymphoma, Non-Hodgkin;   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-Cell;   Monoclonal B-Cell Lymphocytosis;   Multiple Myeloma
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years